Bayer's Strategic Pivot Confronts a Fortnight of Legal and Financial Tests

Bayer faces a pivotal legal verdict on glyphosate while advancing key drugs and crops. The outcome will shape its financial recovery amid mixed cash flow forecasts.

Bayer's share price, hovering around €41, is caught between a promising operational transformation and a looming legal verdict that could redefine its financial future. With the stock down roughly 17% from its February peak, analysts are divided on the path ahead, even as the company advances key growth initiatives in agriculture and pharmaceuticals.

The coming days are densely packed with critical events. Shareholders will gather for the Annual General Meeting on April 24, where a dividend of €0.11 per share and the election of two new supervisory board members are on the agenda. Just three days later, on April 27, the U.S. Supreme Court will hear oral arguments in the case of Durnell v. Monsanto. This hearing will determine whether federal law preempts state-level liability claims concerning glyphosate warning labels, with a ruling expected by June. The outcome could dramatically alter the company's litigation risk profile and provisions.

Simultaneously, Bayer is navigating the final stages of a separate, massive legal settlement. A preliminary approval was granted in March for a $7.25 billion deal to resolve existing and future non-Hodgkin lymphoma claims linked to glyphosate. Claimants have until June 4 to opt out of this arrangement. The Supreme Court's broader stance on preemption could significantly influence the finalization and scope of this settlement. Management has pointed to 2027 as a potential turning point for financial recovery, making favorable legal developments crucial.

Amid these legal headwinds, Bayer's operational engine shows signs of strength. In its Crop Science division, the company is aggressively scaling testing of short-stature corn in the U.S. Midwest, planting the new variety across approximately 200,000 hectares this year. The technology, designed to minimize harvest losses from severe storms, is viewed as a compelling sales argument in the face of increasing weather extremes and a key to defending market leadership.

The Pharmaceuticals division is providing fundamental momentum. The drug Kerendia, which received an expanded EU approval in late March for treating heart failure, is now targeted for peak sales exceeding €3 billion. It joins Nubeqa as a product outperforming market expectations. This growth is vital to offset patent expirations for former blockbusters Xarelto and Eylea. The pipeline holds further promise with candidates like Asundexian and Lynkuet awaiting launch.

Financially, the picture is mixed. The company expects a negative free cash flow in 2026, pressured by payouts for ongoing litigation. However, net debt stood at €29.8 billion at the end of 2025, an 8.5% reduction from the prior year. For the full year, Bayer targets currency-adjusted sales of €45–47 billion and EBITDA before special items of €9.6–10.1 billion. Analyst consensus for the current fiscal year estimates earnings per share around €4.29.

This sets the stage for the Q1 earnings report on May 12. UBS analyst Matthew Weston, who reaffirms a "Buy" rating with a €52 price target—implying roughly 30% upside—expects results in line with consensus. He believes the focus will be on pharmaceutical growth drivers and any potential impact of the Iran conflict on the agricultural chemicals business. The recent introduction of U.S. tariffs on pharmaceutical imports is not expected to alter forecasts, as such scenarios are already factored into financial planning, according to U.S. chief Sebastian Guth.

Sentiment among market observers is shifting. DZ Bank recently upgraded its rating from "Sell" to "Hold," raising its fair value estimate to €44. With the stock having already rallied nearly 95% over the past 12 months, much recovery potential appears priced in. The Supreme Court's decision in June will now set the definitive framework for Bayer's fundamental valuation, determining whether its operational progress can finally be decoupled from its legal legacy.